Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
462 articles with Nektar Therapeutics
-
Nektar Therapeutics Announces First Quarter 2006 Results
5/11/2006
-
Nektar Therapeutics Sets Announcement Date And Conference Call For The First Quarter 2006
5/2/2006
-
Morgan Stanley Global Healthcare Unplugged Conference To Webcast Nektar Therapeutics Corporate Presentation
5/1/2006
-
Ninth Annual Lehman Brothers Global Healthcare Conference To Webcast Nektar Therapeutics Corporate Presentation
3/6/2006
-
Nektar Therapeutics Announces Financial Results For The Year And Fourth Quarter 2005
3/1/2006
-
Nektar Therapeutics Sets Announcement Date And Conference Call For The Year And Fourth Quarter 2005
2/22/2006
-
Nektar Therapeutics Announces That U.S. FDA Has Granted Orphan Drug Designation To The First Amphotericin B Inhalation Powder To Prevent Pulmonary Fungal Infections In Immunosuppressed Patients
2/14/2006
-
Biotechnology Industry Organization (BIO) And Investor Conference To Webcast Nektar Therapeutics Corporate Presentation
2/10/2006
-
Nektar Therapeutics CEO To Retire; Executive Chairman Appointed Acting CEO
2/8/2006
-
Merrill Lynch To Webcast Nektar Therapeutics Corporate Presentation
2/2/2006
-
European Commission Approves Pfizer Inc.'s Exubera(R) For Treatment Of Type 1 And Type 2 Diabetes
1/26/2006
-
Nektar Therapeutics Says Drapeau To Replace Bansal As CFO
1/20/2006
-
Pfizer Inc. (PFE) To Purchase Sanofi-Aventis (SASY.PA) Rights To Exubera(R) For $1.3 Billion
1/13/2006
-
Nektar Therapeutics Presentation To Be Webcast At Informed Investors Biotechnology & Healthcare Investor Forum
12/6/2005
-
SG Cowen & Co., LLC To Webcast Nektar Therapeutics's Corporate Presentation
11/7/2005
-
Nektar Therapeutics Announces Third Quarter 2005 Financial Results
11/4/2005
-
US FDA Delays Decision For Sanofi-Aventis (France) Inhaled Insulin
10/28/2005
-
Nektar Therapeutics Announces Closing Of AeroGen, Inc. Acquisition
10/21/2005
-
The Week In Review: From Optimism To Pessimism In Three Short Weeks
3/27/2005
-
Ten Drugs To Watch
2/24/2005